VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EMN 2021 | Pomalidomide and dexamethasone for R/R AL amyloidosis

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, outlines the results of a retrospective study analyzing the use of pomalidomide and dexamethasone as therapy for patients with relapsed/refractory (R/R) immunoglobin light-chain (AL) amyloidosis. The study analyzed data from 153 previously treated patients with systemic AL amyloidosis who were treated with 28-day cycles of pomalidomide and dexamethasone. After the completion of six cycles, 44% of patients had obtained at least a partial hematologic response, with 3% achieving complete responses and 23% achieving very good partial responses. Furthermore, hematologic response was associated with improved overall survival and progression-free survival. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter